The generated drug can be utilized as a potent tool forsite-specific conjugation, predicting specificity in vitroactivities with extended range against PD-L1 positive cancer cells and can beutilized for further in vivo testing and clinical therapeuticsdevelopment. This evidence concerns the gene CD274 and cancer.